DHPC – Senvelgo® ad us.vet. (velagliflozine)
Known risk of diabetic ketoacidosis (DKA) in cats with diabetes mellitus associated with the use of the product
11.09.2024
| Preparation |
Senvelgo® 15 mg/ml ad us. vet., Lösung zum Eingeben für Katzen |
| Marketing authorisation number |
68958 |
| Active substance |
Velagliflozine |
| Authorization holder |
Boehringer Ingelheim Schweiz GmbH, Basel |
Boehringer Ingelheim Schweiz GmbH, in agreement with Swissmedic, provides information on important measures for the safe use of Senvelgo®, including in situations requiring immediate intervention.
Detailed information can be found in the pdf document.
Company information letter
